Tiger Management-related hedge funds Viking Global Investors and Falcon Edge Capital stand to benefit from the initial public offering of AbCellera Biologics, the company that with Eli Lilly has developed an antibody treatment for Covid-19.
AbCellera, which recently received emergency use authorization from the Food and Drug Administration, disclosed in a regulatory filing this week that it has set a price range for its IPO at $14 to $17 a share.
